AgeX Therapeutics Stock Price, News & Analysis (NYSE:AGE) $0.36 -0.04 (-10.13%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$0.35▼$0.3950-Day Range$0.37▼$0.7852-Week Range$0.33▼$1.00Volume74,692 shsAverage Volume78,776 shsMarket Capitalization$13.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media About AgeX Therapeutics Stock (NYSE:AGE)AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.Read More AGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGE Stock News HeadlinesNovember 17, 2023 | msn.comWhat's Going On With Penny Stock AgeX Therapeutics?November 17, 2023 | finance.yahoo.comSerina Therapeutics Announces POZ Polymer Technology License Agreement with PfizerNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 14, 2023 | msn.comAgeX Therapeutics GAAP EPS of -$0.14, revenue of $0.06MNovember 14, 2023 | finance.yahoo.comAgeX Therapeutics Reports Third Quarter 2023 Financial ResultsNovember 6, 2023 | benzinga.comObesity Pipeline | Clinical Trials, Key Companies – Aardvark, Adocia, Agentix AgeX TherapeuticsAugust 31, 2023 | msn.comSerina Therapeutics to merge with subsidiary of AgeXAugust 30, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether AgeX Therapeutics, Inc. has obtained a Fair Price in its transaction with SerinaNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comAugust 30, 2023 | seekingalpha.comSerina Therapeutics and Agex Therapeutics enter merger agreementAugust 30, 2023 | marketwatch.comAgeX Therapeutics Shares Rise Premarket on Reverse Merger Deal >AGEAugust 30, 2023 | finance.yahoo.comSerina Therapeutics and AgeX Therapeutics Enter into Merger AgreementAugust 14, 2023 | finance.yahoo.comAgeX Therapeutics Reports Second Quarter 2023 Financial ResultsJuly 24, 2023 | finance.yahoo.comAgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred StockJuly 21, 2023 | seekingalpha.comAgeX issues preferred stock to Juvenescence to nix $36M debtJune 28, 2023 | finance.yahoo.com25 States with the Highest Life Expectancy in the USMay 17, 2023 | finance.yahoo.comNYSE American to Suspend Trading Immediately in AgeX Therapeutics, Inc. (AGE) and Commence Delisting ProceedingsMay 17, 2023 | businesswire.comCORRECTING and REPLACING NYSE American to Commence Delisting Proceedings Against AgeX Therapeutics, Inc. (AGE)May 12, 2023 | seekingalpha.comAgeX Therapeutics GAAP EPS of -$0.09, revenue of $0.01MMay 12, 2023 | marketwatch.comAgeX Therapeutics Says Projected Cash Flows Raise Going Concern DoubtsMay 12, 2023 | finance.yahoo.comAgeX Therapeutics Reports First Quarter 2023 Financial ResultsMarch 31, 2023 | finance.yahoo.comAgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial ResultsMarch 30, 2023 | seekingalpha.comAGE AgeX Therapeutics, Inc.March 16, 2023 | msn.comTonix starts enrollment in mid-stage study of depression drug TNX-601 ERMarch 16, 2023 | msn.comAgeX Therapeutics gets $10M loan ahead of potential restructuringFebruary 21, 2023 | 247wallst.comJuvenescence Now Owns 75.60% of AgeX TherapeuticsFebruary 13, 2023 | marketwatch.comAnti-Senescence Therapy Market Industry Analysis Database for Period from 2023-2028See More Headlines Receive AGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AgeX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today11/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:AGE CUSIPN/A CIK1708599 Webwww.agexinc.com Phone(510) 671-8370Fax510-871-4154Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,460,000.00 Net Margins-14,946.81% Pretax Margin-15,014.89% Return on EquityN/A Return on Assets-139.60% Debt Debt-to-Equity RatioN/A Current Ratio0.36 Quick Ratio0.36 Sales & Book Value Annual Sales$30,000.00 Price / Sales449.08 Cash FlowN/A Price / Cash FlowN/A Book Value($0.73) per share Price / Book-0.49Miscellaneous Outstanding Shares37,950,000Free Float35,484,000Market Cap$13.47 million OptionableNot Optionable Beta1.71 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Joanne M. Hackett Ph.D. (Age 44)Independent Interim CEO & Chairman of the Board Comp: $55.74kMs. Eun-Jae Park CPA (Age 51)Chief Financial Officer Comp: $295.29kDr. Nafees Naseer Malik M.D. (Age 45)Chief Operating Officer Comp: $282.27kDr. Ivan LabatChief Information OfficerMs. Judith Segall (Age 70)Secretary Key CompetitorsVBI VaccinesNASDAQ:VBIVOnconova TherapeuticsNASDAQ:ONTXImpel PharmaceuticalsNASDAQ:IMPLOrgenesisNASDAQ:ORGSLandos BiopharmaNASDAQ:LABPView All CompetitorsInstitutional OwnershipSigma Planning CorpBought 41,685 shares on 11/6/2023Ownership: 0.478%View All Institutional Transactions AGE Stock Analysis - Frequently Asked Questions How have AGE shares performed in 2023? AgeX Therapeutics' stock was trading at $0.5519 at the start of the year. Since then, AGE shares have decreased by 35.7% and is now trading at $0.3550. View the best growth stocks for 2023 here. How were AgeX Therapeutics' earnings last quarter? AgeX Therapeutics, Inc. (NYSE:AGE) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.14) earnings per share for the quarter. The firm had revenue of $0.07 million for the quarter. What other stocks do shareholders of AgeX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AgeX Therapeutics investors own include Biocept (BIOC), Allena Pharmaceuticals (ALNA), Co-Diagnostics (CODX), Moleculin Biotech (MBRX), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), AIM ImmunoTech (AIM), AzurRx BioPharma (AZRX) and Digital Ally (DGLY). Who are AgeX Therapeutics' major shareholders? AgeX Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Sigma Planning Corp (0.48%). View institutional ownership trends. How do I buy shares of AgeX Therapeutics? Shares of AGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:AGE) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AgeX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.